Discovery of an Amino Acid-Modified Near-Infrared Aza-BODIPY Photosensitizer as an Immune Initiator for Potent Photodynamic Therapy in Melanoma.
Zhiliang YuHong WangZhongjian ChenXiaochun DongWeili ZhaoYuling ShiQuangang ZhuPublished in: Journal of medicinal chemistry (2022)
The discovery of novel photosensitizers with potent phototoxicity and desirable water solubility is an urgent task for photodynamic therapy. Herein, a series of amino acid-modified aza-BODIPY photosensitizers were synthesized and evaluated. These new PSs exhibited enhanced aqueous solubility, increased 1 O 2 generation efficiency, and an improved photo-dark toxicity ratio. Aspartic acid-modified PS of 1a , which possessed intense NIR absorption and high 1 O 2 quantum yield, demonstrated the most potent efficacy toward the investigated tumor cell lines without using an emulsifier. Subcellular localization, cell-based ROS production, and cell death pathway of 1a were studied. In vivo fluorescence imaging and ex vivo organ distribution assays manifested that 1a possessed reasonable distribution and clearance. In vivo PDT studies indicated that 1a revealed advantages over Ce6 and our previously optimized PS of BDP-4 . It not only afforded an excellent PDT effect with a low drug dose under only single-time photoirradiation but also induced an antitumor immunological response.
Keyphrases
- photodynamic therapy
- fluorescence imaging
- amino acid
- cell death
- high throughput
- small molecule
- single cell
- anti inflammatory
- fluorescent probe
- living cells
- oxidative stress
- drug induced
- ionic liquid
- case control
- high resolution
- energy transfer
- oxide nanoparticles
- single molecule
- electronic health record
- monte carlo
- high speed